Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Phase 2 Unknown 50 enrolled Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II study of KN046 plus platinum-based doublet chemotherapy in previously untreated advanced non-squamous and squamous NSCLC subjects. The study will assess primarily the safety and efficacy of KN046 plus platinum-based doublet chemotherapy.

Timeline

Start: 2019-09-04
Primary completion: 2021-03-01
Completion: 2021-06-01

Publications

Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, Yang S, Xu T, Liu Y, Wang N, Zhang L, Huang Y. KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. Cell Rep Med. 2024 Mar 19;5(3):101470. doi: 10.1016/j.xcrm.2024.101470.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ERFONRILIMAB	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Paclitaxel	Small molecule	500 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Summary

Timeline

Publications

Drugs

Indications